XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT AND GEOGRAPHIC INFORMATION
 6 Months Ended
Jun. 30, 2013
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION
SEGMENT AND GEOGRAPHIC INFORMATION

The Company reports segment information on the “management” approach which designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has determined that its Chief Executive Officer is the Company’s chief operating decision maker (“CODM”) as he is responsible for reviewing and approving investments in the Company’s technology platforms and manufacturing infrastructure. Prior to 2012, the Company was organized as one reportable operating segment. Subsequent to the Acquisition, the Company’s business was reorganized into two reportable operating segments for financial reporting purposes, Affymetrix Core and eBioscience.

In 2012, the Company reorganized its business in the following four business units: Expression, Genetic Analysis and Clinical Applications, Life Science Reagents and Corporate. The Expression business unit markets the Company’s gene expression products and services, including in vitro transcription and other whole transcript arrays and associated reagents and software and our QuantiGene line comprised of low-to-mid-plex RNA analysis products. The Genetic Analysis and Clinical Applications business unit markets the Company’s genotyping and clinical array-systems, including cytogenetics products. The Life Science Reagents business unit targets the life science reagent markets, marketing reagents, enzymes, purification kits and biochemicals used by life science researchers. The Corporate business unit is comprised primarily of revenue from royalty arrangements, and field revenue from services provided to customers by the Company. The Company determined that its manufacturing operations are centralized and based on platforms that are used to produce various products that serve multiple applications and markets. Additionally, the business units share research, development and common corporate services that provide capital, infrastructure and functional support. Based on the facts and circumstances, the Company concluded that the four business units represent one reportable operating segment, Affymetrix Core.

The Company’s other reportable operating segment, eBioscience, was acquired in the second quarter of 2012 and operates as a separate business unit. eBioscience specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry reagents, immunoassays, microscopic imaging and other protein-based analyses. The Acquisition allows the Company to expand addressable markets and continue to diversify the business beyond genomics discovery into cell and protein analysis.

The Company evaluates the performance of its reportable operating segments based on revenue and income (loss) from operations. Revenue is allocated to each business unit based on product codes excluding eBioscience whose business is primarily operated on a stand-alone basis.

The following table shows revenue and loss from operations by reportable operating segment for the three and six months ended June 30, 2013 and 2012 (in thousands):

 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2013
 
2012
 
2013
 
2012
Revenue:
 
 
 
 
 
 
 
Affymetrix Core
$
60,618

 
$
65,027

 
$
119,555

 
$
130,274

eBioscience
18,846

 
1,376

 
37,854

 
1,376

Totals
$
79,464

 
$
66,403

 
$
157,409

 
$
131,650

Loss from operations:
 
 
 
 
 
 
 
Affymetrix Core
$
1,251

 
$
(15,552
)
 
$
(6,590
)
 
$
(18,904
)
eBioscience
(4,202
)
 
159

 
(8,567
)
 
159

Totals
$
(2,951
)
 
$
(15,393
)
 
$
(15,157
)
 
$
(18,745
)